10-Q: Immunic Inc Reports Financial Results and Operational Progress for Q2 2024

Immunic Inc, a biotechnology firm specializing in oral immunology therapies, announced its second-quarter financial results and updates on its clinical development programs.

Summary

• Immunic Inc is a biotechnology company focused on developing oral immunology therapies for chronic inflammatory and autoimmune diseases.
• The company's lead candidate, vidofludimus calcium (IMU-838), is in Phase 3 and Phase 2 clinical trials for relapsing and progressive multiple sclerosis (MS), respectively.
• The company reported positive interim data from the Phase 2 CALLIPER trial of vidofludimus calcium in progressive MS in October 2023, with topline data expected in April 2025.
• The company is also developing IMU-856 for gastrointestinal diseases and IMU-381, a next-generation molecule for gastrointestinal diseases.
• As of June 30, 2024, Immunic had cash and cash equivalents of $79.7 million.
• The company's accumulated deficit was $461.9 million as of June 30, 2024.
• Immunic raised $80 million in gross proceeds from a private placement in January 2024, with potential for up to an additional $160 million in future tranches.
• The company's operating expenses for the six months ended June 30, 2024, were $46.7 million, down from $52.3 million in the same period in 2023.
• The company does not have adequate liquidity to fund its operations for at least twelve months from the issuance of these consolidated financial statements without raising additional capital and such actions are not solely within the control of the Company.
• If the Company is unable to obtain additional capital, it would have a material adverse effect on the operations of the Company, its clinical development program, and the Company may have to cease operations altogether.

Sentiment

Score: 3

Explanation: The sentiment is low due to the company's significant net loss, accumulated deficit, and the need for additional funding to continue operations. While there are positive developments in the clinical pipeline, the financial situation and uncertainty around future capital raises weigh heavily on the overall sentiment.

Positives

• Positive interim data from the Phase 2 CALLIPER trial of vidofludimus calcium in progressive MS, reinforcing its neuroprotective potential.
• Phase 1b trial of IMU-856 in celiac disease patients showed positive effects in four key dimensions of the disease.
• Successful $80 million private placement in January 2024, providing funding for ongoing clinical development.
• Notice of Allowance received for a composition-of-matter patent for a specific polymorph of vidofludimus calcium in the United States, providing protection into 2039.
• Publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting MS in a peer-reviewed journal.
• Appointment of a new Chief Operating Officer and President, Jason Tardio, to lead preparations for the potential launch of vidofludimus calcium.
• Promotion of Werner Gladdines to Chief Development Officer.
• Appointment of Simona Skerjanec to the Board of Directors, bringing expertise in drug development and commercialization.

Negatives

• The company has no products approved for sale and has never been profitable.
• Accumulated deficit of $461.9 million as of June 30, 2024.
• Operating losses are expected to continue in the foreseeable future.
• The company does not have adequate liquidity to fund its operations for at least twelve months from the issuance of these consolidated financial statements without raising additional capital.
• Research and development expenses decreased due to deprioritizing the izumerogant program and completion of the phase 1 trial of IMU-856 in celiac disease.
• General and administrative expenses increased due to higher personnel costs and legal/consultancy fees.

Risks

• The company may not have adequate liquidity to fund its operations for at least twelve months from the issuance of these consolidated financial statements without raising additional capital.
• Failure to obtain needed additional funding on acceptable terms, if at all, could force the company to curtail product development programs or liquidate assets.
• Clinical trials may fail to meet their endpoints or demonstrate safety and efficacy.
• Regulatory approval may not be obtained for product candidates.
• The company may not be able to successfully commercialize any approved products.
• Dependence on third parties for manufacturing and clinical trials.
• Competition from other companies developing treatments for the same indications.
• Potential for product liability claims.
• The company may not be able to protect its intellectual property.
• Changes in laws and regulations could adversely affect the company's business.

Future Outlook

Immunic expects to continue incurring significant expenses and increasing operating losses for the foreseeable future as it advances its clinical development programs. The company anticipates reporting an interim futility analysis of the ENSURE program in Q4 2024 and topline data from the CALLIPER trial in April 2025. Completion of the ENSURE trials is expected in Q2 2026 and 2H 2026. Immunic is also preparing for Phase 2 testing of IMU-856 and continuing preclinical testing of IMU-381.

Management Comments

• The company highlighted the positive interim data from the CALLIPER trial and the progress of the ENSURE program.
• Management emphasized the potential of vidofludimus calcium's combined neuroprotective, anti-inflammatory, and antiviral effects.
• The company expressed confidence in the potential of IMU-856 and IMU-381 for gastrointestinal diseases.
• Management acknowledged the need for additional funding to continue operations and advance the clinical pipeline.

Industry Context

Immunic's focus on oral immunology therapies aligns with the growing trend of developing convenient and patient-friendly treatments for chronic inflammatory and autoimmune diseases. The company's lead candidate, vidofludimus calcium, targets multiple pathways involved in MS, potentially offering a differentiated approach compared to existing therapies. The development of IMU-856 and IMU-381 for gastrointestinal diseases addresses a significant unmet need in this area.

Comparison to Industry Standards

• Vidofludimus calcium's mechanism of action, targeting DHODH and Nurr1, is similar to Teriflunomide (Aubagio by Sanofi) which also inhibits DHODH. However, vidofludimus calcium's added neuroprotective potential via Nurr1 activation differentiates it. In the Phase 2 EMPhASIS trial, vidofludimus calcium showed a 62% reduction in the cumulative number of new active T1-weighted lesions compared to placebo, which is comparable to the 57% reduction seen with Aubagio in its TEMSO trial. However, the trials had different patient populations and endpoints, making direct comparisons difficult.
• IMU-856's targeting of SIRT6 for restoring intestinal barrier function is a novel approach compared to currently approved treatments for celiac disease, which primarily focus on gluten-free diets or immunosuppression. For example, Larazotide acetate (Innovate Biopharmaceuticals) is in Phase 3 trials for celiac disease and aims to reduce intestinal permeability, but through a different mechanism of tight junction regulation. IMU-856's potential to maintain immune surveillance while restoring barrier function could offer an advantage over immunosuppressive agents like Budesonide (used off-label in celiac disease).
• For progressive MS, Ocrelizumab (Ocrevus by Roche) is the only approved disease-modifying therapy. In the ORATORIO trial, Ocrevus reduced the risk of 12-week confirmed disability progression by 24% compared to placebo. Vidofludimus calcium's neuroprotective potential, as suggested by the CALLIPER trial interim data, could offer a different approach to slowing disease progression. However, direct comparisons will only be possible after the completion of the CALLIPER and ENSURE trials.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows.

Related Party Transactions

• On April 17, 2020, the Company and Dr. Duane Nash entered into the Executive Chairman Agreement.
• On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $30,250 per month.
• On October 17, 2023, Immunic, Inc. and Dr. Duane Nash entered into Addendum Number 5 to the Executive Chairman Agreement to extend the term of Dr. Nashs employment as Executive Chairman of the Board of Directors of the Company to December 31, 2024. In connection with Addendum Number 5, the Company increased Dr. Nashs monthly base salary to $32,368 from $30,250 (which includes the cash retainer payable for serving on the Companys Board or for acting as the Chairman of the Board).

Stakeholder Impact

• Shareholders: Potential dilution from future capital raises. Stock price may be negatively impacted by the company's financial situation and the need for additional funding. Successful clinical development and commercialization of product candidates could lead to significant shareholder value.
• Employees: Potential impact on job security if the company is unable to raise sufficient capital. New appointments and promotions indicate investment in leadership and talent.
• Patients: Potential for new and effective treatments for multiple sclerosis and gastrointestinal diseases if the company's product candidates are successful.
• Creditors: Risk of default if the company is unable to raise additional capital and improve its financial position.

Next Steps

• Continue enrollment and dosing in the Phase 3 ENSURE trials and the Phase 2 CALLIPER trial.
• Report interim futility analysis of the ENSURE program in Q4 2024.
• Report topline data from the CALLIPER trial in April 2025.
• Prepare for Phase 2 testing of IMU-856 in patients with ongoing active celiac disease.
• Continue preclinical testing of IMU-381.
• Seek additional funding through equity offerings, debt financings, or strategic collaborations.
• Evaluate potential strategic collaborations for each product candidate.

Key Dates

Keywords

immunology therapies, autoimmune diseases, inflammatory diseases, vidofludimus calcium, IMU-838, multiple sclerosis, relapsing multiple sclerosis, progressive multiple sclerosis, IMU-856, gastrointestinal diseases, celiac disease, inflammatory bowel disease, IMU-381, clinical trials, biotechnology, drug development